CTMX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

CytomX Therapeutics Inc

NASDAQ | CTMX

4.01

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 4, 2025)

$588.74M

Market Cap

7.14

P/E Ratio

0.5

EPS

$4.16

52 Week High

$0.40

52 Week Low

HEALTHCARE

Sector

CTMX Chart

Recent Chart
Price Action

CTMX Technicals

Tags:

CTMX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $138M
Total Revenue $138M
Cost Of Revenue $1.8M
Costof Goods And Services Sold $1.8M
Operating Income $25M
Selling General And Administrative $30M
Research And Development $83M
Operating Expenses $113M
Investment Income Net -
Net Interest Income $7.1M
Interest Income $7.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax $32M
Income Tax Expense $224K
Interest And Debt Expense -
Net Income From Continuing Operations $32M
Comprehensive Income Net Of Tax -
Ebit $25M
Ebitda $27M
Net Income $32M

Revenue & Profitability

Earnings Performance

CTMX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $121M
Total Current Assets $107M
Cash And Cash Equivalents At Carrying Value $38M
Cash And Short Term Investments $38M
Inventory -
Current Net Receivables $3.1M
Total Non Current Assets $13M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $583K
Intangible Assets Excluding Goodwill $583K
Goodwill $949K
Investments -
Long Term Investments -
Short Term Investments $63M
Other Current Assets $3.6M
Other Non Current Assets -
Total Liabilities $121M
Total Current Liabilities $86M
Current Accounts Payable $1.1M
Deferred Revenue -
Current Debt -
Short Term Debt $10M
Total Non Current Liabilities $35M
Capital Lease Obligations $9.4M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $9.4M
Other Current Liabilities $7.2M
Other Non Current Liabilities $4.1M
Total Shareholder Equity -$456K
Treasury Stock -
Retained Earnings -$692M
Common Stock $1K
Common Stock Shares Outstanding $85M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$86M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.8M
Capital Expenditures $310K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $100M
Cashflow From Financing $7.5M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $32M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $138M
Total Revenue $138M
Cost Of Revenue $1.8M
Costof Goods And Services Sold $1.8M
Operating Income $25M
Selling General And Administrative $30M
Research And Development $83M
Operating Expenses $113M
Investment Income Net -
Net Interest Income $7.1M
Interest Income $7.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax $32M
Income Tax Expense $224K
Interest And Debt Expense -
Net Income From Continuing Operations $32M
Comprehensive Income Net Of Tax -
Ebit $25M
Ebitda $27M
Net Income $32M

CTMX News

CTMX Profile

CytomX Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

CytomX Therapeutics, Inc., based in South San Francisco, California, is a pioneering biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary Probodyâ„¢ technology platform. This innovative approach aims to create highly selective therapeutics that reduce off-tumor effects while enhancing targeted anti-tumor activity, addressing critical unmet needs in oncology. With a promising pipeline of product candidates at various clinical stages, CytomX is well-positioned to improve patient outcomes and transform cancer treatment paradigms. The company's strategic emphasis on partnerships and collaborations further enhances its potential to make a significant impact within the biopharmaceutical sector.

PTLE
+39.11%
$0.25
VHAI
+21.21%
$0.00
MSPR
+39.09%
$0.72
SCNX
+19.27%
$0.84
NVDA
-3.06%
$200.54
PFE
-1.48%
$24.29
BYND
+0.33%
$1.39
ORIS
+29.47%
$0.20
HTZ
+40.45%
$6.93
AMZN
+4.00%
$254.00
CHR
+7.07%
$0.13
CAPT
+23.78%
$0.62
GRAB
+0.99%
$6.07
PLTR
-7.18%
$192.29
ASST
-5.11%
$1.20
WTO
-4.90%
$0.05
NFE
+11.73%
$1.31
AXDX
-61.36%
$0.03
PLUG
-6.00%
$2.58
EPWK
+3.73%
$0.07
DNN
-4.79%
$2.78
ONDS
+0.54%
$6.18
NOK
+3.47%
$7.15
BURU
-6.99%
$0.31
YDKG
-10.37%
$0.05
TSLA
-3.68%
$451.09
INTC
-4.92%
$37.55
BITF
-4.96%
$3.90
GPUS
-9.41%
$0.34
ADAP
-15.14%
$0.05
ETHD
+16.97%
$5.08
CIFR
-1.44%
$22.43
HIMS
+0.20%
$44.47
F
-1.57%
$12.80
SOFI
-1.86%
$30.05
RMBL
+60.50%
$3.21
VSEE
+1.51%
$1.00
ADD
-25.47%
$0.05
ACHR
-4.71%
$9.92
CAN
-14.52%
$1.11
TLRY
-5.72%
$1.23
SRM
+53.27%
$10.30
NCLH
-14.61%
$18.93
RUBI
+26.65%
$0.87
AMCR
-0.50%
$7.86
KVUE
+0.03%
$16.14
UBER
-6.10%
$93.63
META
-1.64%
$637.71
PLTZ
+14.72%
$5.99
AAL
-4.23%
$12.77
IREN
+2.11%
$69.17
T
-0.79%
$24.33
MARA
-4.43%
$17.02
BTBT
-6.57%
$3.19
BTG
-4.82%
$4.04
SOUN
-10.60%
$15.29
VALE
-1.92%
$11.96
LAES
-13.07%
$6.45
BMNR
-6.06%
$40.26
WULF
-3.07%
$15.60
KDLY
-4.41%
$0.88
WLGS
-5.57%
$0.04
RXRX
-6.33%
$5.09
NEHC
+11.56%
$6.32
AMD
-2.47%
$253.23
NVTS
-12.73%
$10.68
SNAP
-2.94%
$7.58
RGTI
-4.67%
$37.29
NIO
-2.22%
$7.25
ETWO
0.00%
$3.30
NGD
-8.10%
$6.69
RIVN
-4.73%
$12.56
AAPL
+0.58%
$270.61
BAC
-0.24%
$53.42
DENN
+50.00%
$6.16
AMC
-0.38%
$2.58
CCL
-9.03%
$26.11
PRLD
-57.03%
$1.70
DVLT
-5.65%
$1.73
PLTD
+7.99%
$6.35
AFMD
-34.94%
$0.18
RIG
-2.77%
$3.85
QBTS
-7.10%
$30.74
LUMN
-9.12%
$10.75
NVO
-1.50%
$48.36
IONZ
+14.52%
$4.37
UUUU
-4.05%
$17.07
IHRT
+34.70%
$3.92
RANI
+6.04%
$2.27
BMY
-0.10%
$46.02
CGC
-6.25%
$1.12
FUBO
+5.63%
$3.65
KLG
-9.05%
$13.35
MSAI
-33.32%
$1.32
PHGE
-16.03%
$0.41
SAGT
+25.14%
$2.35
GRYP
-10.38%
$1.38
APLD
-5.56%
$31.04
MODV
-25.22%
$0.43
NAKA
-10.16%
$0.79
PTLE
+39.11%
$0.25
VHAI
+21.21%
$0.00
MSPR
+39.09%
$0.72
SCNX
+19.27%
$0.84
NVDA
-3.06%
$200.54
PFE
-1.48%
$24.29
BYND
+0.33%
$1.39
ORIS
+29.47%
$0.20
HTZ
+40.45%
$6.93
AMZN
+4.00%
$254.00
CHR
+7.07%
$0.13
CAPT
+23.78%
$0.62
GRAB
+0.99%
$6.07
PLTR
-7.18%
$192.29
ASST
-5.11%
$1.20
WTO
-4.90%
$0.05
NFE
+11.73%
$1.31
AXDX
-61.36%
$0.03
PLUG
-6.00%
$2.58
EPWK
+3.73%
$0.07
DNN
-4.79%
$2.78
ONDS
+0.54%
$6.18
NOK
+3.47%
$7.15
BURU
-6.99%
$0.31
YDKG
-10.37%
$0.05
TSLA
-3.68%
$451.09
INTC
-4.92%
$37.55
BITF
-4.96%
$3.90
GPUS
-9.41%
$0.34
ADAP
-15.14%
$0.05
ETHD
+16.97%
$5.08
CIFR
-1.44%
$22.43
HIMS
+0.20%
$44.47
F
-1.57%
$12.80
SOFI
-1.86%
$30.05
RMBL
+60.50%
$3.21
VSEE
+1.51%
$1.00
ADD
-25.47%
$0.05
ACHR
-4.71%
$9.92
CAN
-14.52%
$1.11
TLRY
-5.72%
$1.23
SRM
+53.27%
$10.30
NCLH
-14.61%
$18.93
RUBI
+26.65%
$0.87
AMCR
-0.50%
$7.86
KVUE
+0.03%
$16.14
UBER
-6.10%
$93.63
META
-1.64%
$637.71
PLTZ
+14.72%
$5.99
AAL
-4.23%
$12.77
IREN
+2.11%
$69.17
T
-0.79%
$24.33
MARA
-4.43%
$17.02
BTBT
-6.57%
$3.19
BTG
-4.82%
$4.04
SOUN
-10.60%
$15.29
VALE
-1.92%
$11.96
LAES
-13.07%
$6.45
BMNR
-6.06%
$40.26
WULF
-3.07%
$15.60
KDLY
-4.41%
$0.88
WLGS
-5.57%
$0.04
RXRX
-6.33%
$5.09
NEHC
+11.56%
$6.32
AMD
-2.47%
$253.23
NVTS
-12.73%
$10.68
SNAP
-2.94%
$7.58
RGTI
-4.67%
$37.29
NIO
-2.22%
$7.25
ETWO
0.00%
$3.30
NGD
-8.10%
$6.69
RIVN
-4.73%
$12.56
AAPL
+0.58%
$270.61
BAC
-0.24%
$53.42
DENN
+50.00%
$6.16
AMC
-0.38%
$2.58
CCL
-9.03%
$26.11
PRLD
-57.03%
$1.70
DVLT
-5.65%
$1.73
PLTD
+7.99%
$6.35
AFMD
-34.94%
$0.18
RIG
-2.77%
$3.85
QBTS
-7.10%
$30.74
LUMN
-9.12%
$10.75
NVO
-1.50%
$48.36
IONZ
+14.52%
$4.37
UUUU
-4.05%
$17.07
IHRT
+34.70%
$3.92
RANI
+6.04%
$2.27
BMY
-0.10%
$46.02
CGC
-6.25%
$1.12
FUBO
+5.63%
$3.65
KLG
-9.05%
$13.35
MSAI
-33.32%
$1.32
PHGE
-16.03%
$0.41
SAGT
+25.14%
$2.35
GRYP
-10.38%
$1.38
APLD
-5.56%
$31.04
MODV
-25.22%
$0.43
NAKA
-10.16%
$0.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.